How will new EU Directives 2001/20/EC and 2005/28/EC affect clinical trials in CEE?
The EU has revamped its pharmaceuticals website, but is its 'entertaining' vision a skewered one? Reflector reports.
Reflector welcomes an instance of common sense making a breakthrough in Brussels.
Stuart Tutt advocates a calm response to the ongoing parallel trade controversy.
Oncology companies need to rethink their pricing and reimbursement plans in the face of more NICE-style barriers emerging across Europe.
A global look at some of the issues that are set to affect compliance in the coming year.
Stephen Rose assesses the fallout of the recent antitrust raids on pharma.
Ton van Lierop, from the cabinet of European Commission vice president Günter Verheugen, talks to Pharm Exec Europe about the EC’s ongoing fight against fake medicines.
Sarah Houlton outlines the deals, collaborations and controversies that shaped the pharmaceutical industry in 2007, and examines how the land lies as we prepare for 2008.
